# Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis

> **NCT03316781** · PHASE3 · COMPLETED · sponsor: **Shanghai Henlius Biotech** · enrollment: 262 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** HLX03
- **DRUG:** adalimumab

## Key facts

- **NCT ID:** NCT03316781
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-27
- **Primary completion:** 2018-07-15
- **Final completion:** 2019-04-22
- **Target enrollment:** 262 (ACTUAL)
- **Last updated:** 2025-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03316781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03316781, "Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03316781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*